title: Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
abstract: Human immunodeficiency virus-infected women (n=16) received indinavir (800 mg three times a day) plus zidovudine plus lamivudine from 14 to 28 weeks of gestation to 12 weeks postpartum. Two women and eight infants experienced grade 3 or 4 toxicities that were possibly treatment related. Indinavir area under the plasma concentration-time curve was 68% lower antepartum versus postpartum, suggesting increased intestinal and/or hepatic CYP3A activity during pregnancy.
authors.affiliation: Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA. jash@u.washington.edu
authors.forename: Jashvant D
authors.initials: JD
authors.lastname: Unadkat
authors.forename: Diane W
authors.initials: DW
authors.lastname: Wara
authors.forename: Michael D
authors.initials: MD
authors.lastname: Hughes
authors.forename: Anita A
authors.initials: AA
authors.lastname: Mathias
authors.forename: Diane T
authors.initials: DT
authors.lastname: Holland
authors.forename: Mary E
authors.initials: ME
authors.lastname: Paul
authors.forename: James
authors.initials: J
authors.lastname: Connor
authors.forename: Sharon
authors.initials: S
authors.lastname: Huang
authors.forename: Bach-Yen
authors.initials: BY
authors.lastname: Nguyen
authors.forename: D Heather
authors.initials: DH
authors.lastname: Watts
authors.forename: Lynne M
authors.initials: LM
authors.lastname: Mofenson
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Smith
authors.forename: Paul
authors.initials: P
authors.lastname: Deutsch
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Kaiser
authors.forename: Ruth E
authors.initials: RE
authors.lastname: Tuomala
mesh_terms: D000328:Adult; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics; D015497:HIV-1; D006801:Humans; D019469:Indinavir / Q000009:adverse effects / Q000493:pharmacokinetics; D007231:Infant, Newborn; D008099:Liver / Q000378:metabolism; D008297:Male; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*
chemical_list: D017320:HIV Protease Inhibitors; D019469:Indinavir; D051544:Cytochrome P-450 CYP3A